文献速递MDS 与骨髓增殖性肿瘤

高分子风险突变与较低JAK2突变等位基因频率并存对骨髓纤维化患者预后的协同影响——一项多中心研究

Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study.
PubMed 文献 · Leukemia · 2024-10-04

该多中心研究对124例骨髓纤维化患者进行54个髓系肿瘤相关基因的靶向二代测序,并在多个国际中心队列中外部验证。发现在JAK2突变患者中,高分子风险突变仅在较低JAK2V617F等位基因频率者中驱动不良预后;两者并存是独立不良预后因素,且将HMR/JAK2V617F VAF(≤50%)状态整合可显著提升现有预后模型。

要点

  • 在JAK2突变骨髓纤维化患者中,高分子风险突变仅在较低JAK2V617F等位基因频率者中驱动不良预后。
  • 高分子风险突变与较低JAK2V617F VAF并存是独立不良预后因素,不受年龄及MIPSS70、MIPSS70+v2、GIPSS风险分组影响。
  • 将HMR/JAK2V617F VAF(≤50%)状态整合可显著提升现有预后模型,表现为更高的c-index和时间依赖ROC分析结果。

核心结论

  • 在骨髓纤维化患者中,高分子风险突变与较低JAK2V617F等位基因频率并存对预后具有协同不良影响。
  • 高分子风险突变与较低JAK2V617F VAF并存是独立不良预后因素,且将HMR/JAK2V617F VAF(≤50%)状态整合可显著提升现有预后模型。

研究设计与样本

  • 研究对124例骨髓纤维化患者使用靶向二代测序分析54个髓系肿瘤相关基因的突变状态。
  • 分析了来自多个国际中心的三个队列用于外部验证。

主要发现

  • 在JAK2突变患者中,高分子风险突变在较低JAK2V617F VAF患者中驱动不良预后,而在较高JAK2V617F VAF患者中未驱动不良预后。
  • 生存分析在验证队列中显示一致结果。
  • 多变量分析显示,高分子风险突变与较低JAK2V617F VAF并存是独立的不良生存预后因素,不受年龄、MIPSS70、MIPSS70+v2和GIPSS风险分组影响。
  • 突变共现检验显示不同队列间无共享突变模式,排除了其他并发突变的潜在混杂效应。
  • 将HMR/JAK2V617F VAF(≤50%)状态整合显著提升了现有预后模型,表现为更高的c-index和时间依赖ROC分析结果。

关键数值与推荐

  • 高分子风险突变包括ASXL1、EZH2、SRSF2、IDH和U2AF1Q157。
  • JAK2V617F VAF阈值设定为≤50%用于整合预后模型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要单细胞研究和连续随访以解析骨髓纤维化的克隆演化及其与JAK2V617F VAF动态变化的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In addition to high-molecular risk (HMR) mutations (ASXL1, EZH2, SRSF2, IDH, and U2AF1Q157), lower JAK2V617F variant allele frequencies (VAF) have been demonstrated to be associated with poor prognosis of myelofibrosis (MF) patients. Nevertheless, the relationship between JAK2V617F VAF and HMR mutations remains inconclusive. To address this, we analyzed the mutation status of 54 myeloid neoplasm-relevant genes using targeted next-generation sequencing in 124 MF patients. Three cohorts from multiple international centers were analyzed for external validation. Among JAK2-mutated patients, the presence of HMR mutations drove poor prognosis in patients with lower JAK2V617F VAF but not in those with higher JAK2V617F VAF. Survival analyses showed consistent results across validation cohorts. In multivariable analysis, concurrent HMR and a lower JAK2V617F VAF was identified as an independent adverse prognostic factor for survival, irrespective of age, MIPSS70, MIPSS70 + v2, and GIPSS risk groups. Mutation co-occurrence tests revealed no shared mutational pattern over different cohorts, excluding potential confounding effect from other concurrent mutations. Importantly, the integration of HMR/JAK2V617F VAF (≤50%) status significantly enhanced existing prognostic models, as evidenced by higher c-indexes and time-dependent ROC analyses. Single-cell studies with sequential follow-ups are warranted to decipher the clonal evolution of MF and how it relates to JAK2V617F VAF dynamics.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang YH, Wei CH, Lin CC, et al. Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study. Leukemia. 2024. PMID: 39367172. doi:10.1038/s41375-024-02422-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。